Geoffrey T. Gibney, MD, is a co-leader of the Melanoma Disease Group at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, and a member of the Developmental Therapeutics (Phase I) program. He is well known for treating patients with advanced non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma and merkel cell carcinoma), renal cell carcinoma and other rare skin cancers. Dr. Gibney is board certified in both internal medicine and medical oncology. He was previously a faculty member in the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa.
Dr. Gibney is recognized for his advanced melanoma research. He is currently involved in several clinical trials focused on developing novel immunotherapy and targeted therapy strategies. Past clinical research has included the study of anti-PD-1 therapy to prevent recurrences of resected melanoma, combination immunotherapies (such as ipilimumab plus the novel IDO1 inhibitor, epacadostat) to enhance the clinical benefit in advanced melanoma patients and combination BRAF targeted therapy to overcome drug resistance.
His current goal is to develop biomarker-driven approaches for personalized therapeutic strategies in patients with advanced malignancies.
1. NIH/NCI CDP (Moffitt Skin Cancer SPORE Grant; P50) (PI: Gibney) 2013 - 2015 Career Development Award. Title: Cotargeting c-Met and PI3K pathways in NRAS and GNAQ/GNA11 mutant melanoma Description: Investigated adaptive responses to c-Met inhibition and concurrent vertical pathway blockade with combination PI3K inhibition in NRAS and GNAQ mutant melanoma. 2. NIH/NCI P50 (Moffitt Skin Cancer SPORE Grant) (PI: Sondak/Smalley) 2014 - 2015 Co-investigator, Administration and Clinical Trials Title: Moffitt Skin Cancer SPORE – Project Core C Description: Oversaw the phase I clinical trial of vemurafenib plus XL888 in patients with advanced BRAF V600 mutant melanoma as the principal investigator, as well as other SPORE sponsored trials. 3. ACS-IRG (PI: Gibney) 2012 - 2014 Pilot Grant Title: Targeting the c-Met, Axl and PDGFR-β pathways in NRAS mutant melanoma Description: Investigated c-Met, Axl, and PDGFR-β as biomarkers and therapeutic targets in NRAS mutant melanoma.